Second-line Nintedanib Plus Docetaxel for Patients with Lung Adenocarcinoma after Failure on First-Line Immune Checkpoint Inhibitor Combination Therapy: Initial Efficacy and Safety Results from VARGADO Cohort C.
Annals of Oncology（2021）
Key words
Intratumor Heterogeneity
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined